Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1187.82% is in line with its 5-year average of -1103.06%, around the middle of its 5-year range (-1864.64%–-55.17%).
8.23% above its 12-month average of -1294.35%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1648.70%.
EBITDA MARGIN
-1187.82%
EBITDA MARGIN AVG TTM
-1294.35%
EBITDA MARGIN AVG 3Y
-1302.54%
EBITDA MARGIN AVG 5Y
-1103.06%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+8.23%
CURRENT VS 3Y AVG
+8.81%
CURRENT VS 5Y AVG
-7.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Caribou Biosciences, Inc.
Market Cap
$118.02M
EBITDA Margin
-1187.82%
TTM Avg
-1294.35%
3Y Avg
-1302.54%
5Y Avg
-1103.06%
Market Cap
$118.50M
EBITDA Margin
-699.90%
TTM Avg
-1930.94%
3Y Avg
-1689.05%
5Y Avg
-1903.35%
Market Cap
$117.43M
EBITDA Margin
-254.86%
TTM Avg
-347.69%
3Y Avg
-398.28%
5Y Avg
-4102.41%
Market Cap
$118.63M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$116.59M
EBITDA Margin
-408000.00%
TTM Avg
-396456.25%
3Y Avg
-201636.71%
5Y Avg
-201636.71%
Market Cap
$114.24M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.77M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
Market Cap
$111.17M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $118.02M | -1187.82% | -1294.35% | -1302.54% | -1103.06% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -699.90% | -1930.94% | -1689.05% | -1903.35% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -254.86% | -347.69% | -398.28% | -4102.41% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -29.32% | -13.32% | -6.17% | -1.07% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | -408000.00% | -396456.25% | -201636.71% | -201636.71% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -254.71% | -369.64% | -290.17% | -290.17% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 28.85% | 28.85% | 28.85% | 28.85% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | N/A | N/A | N/A | N/A |
Gross Margin
67.3%
EBITDA Margin
-1187.8%
Operating Margin
-1220.5%
Net Margin
-1030.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1648.70% |
| 2026-03-31 | -1069.29% |
| 2025-12-31 | -704.67% |
| 2025-09-30 | -1308.87% |
| 2025-06-30 | -1740.19% |
| 2025-03-31 | -1774.25% |
| 2024-12-31 | -1814.68% |
| 2024-09-30 | -1831.08% |
| 2024-06-30 | -1231.09% |
| 2024-03-31 | -1864.64% |
| 2023-12-31 | -1031.53% |
| 2023-09-30 | -55.17% |
| 2023-06-30 | -858.88% |
| 2023-03-31 | -871.70% |
| 2022-12-31 | -814.52% |
| 2022-09-30 | -789.80% |
| 2022-06-30 | -669.68% |
| 2022-03-31 | -771.21% |
| 2021-12-31 | -786.71% |
| 2021-09-30 | -461.55% |
| 2021-06-30 | -1065.99% |
| 2021-03-31 | -816.77% |
| 2020-12-31 | -1523.68% |
| 2020-09-30 | -668.03% |
| 2020-06-30 | -23.91% |
| 2020-03-31 | -599.82% |
